Kylo-11 phase 1 trial: safety and durable reduction of lipoprotein(a) after single subcutaneous do
This first-in-human, randomised, double-blind, placebo-controlled phase 1 trial evaluated **Kylo-11**, a non-canonical, long-duration small interfering RNA designed to lower **lipoprotein(a)**, in oth...